{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:45:56Z","timestamp":1792057556958,"version":"4.4.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Pancreatic cancer is widely acknowledged as one of the most aggressive malignancies of the digestive system. More than 80% of patients are diagnosed at an advanced stage with an extremely poor prognosis. While contemporary combination chemotherapy and the novel RAS inhibitor daraxonrasib have modestly prolonged survival, clinical benefits remain limited, necessitating less toxic yet more substantial and durable therapeutic strategies. Herein, we report a case of a patient with advanced metastatic adenocarcinoma who achieved disease stability and long-term survival following multidisciplinary treatment incorporating autologous DC-CIK cell therapy. The patient was a 73-year-old male diagnosed with poorly differentiated pancreatic ductal carcinoma 9 years ago. After surgery, he developed pelvic implantation metastases and subsequently received multi-line chemotherapy and radiotherapy. Thereafter, he completed five cycles of DC-CIK cell infusion at a dose of 5\u00d710\n                    <jats:sup>9<\/jats:sup>\n                    ~10\u00d710\n                    <jats:sup>9<\/jats:sup>\n                    cells between November 2018 and December 2019. The patient did not experience any obvious adverse reactions during the treatment. Post-treatment, the patient maintained a stable disease state. Although bone metastasis was detected in February 2021, the patient\u2019s overall survival (OS) and progression-free survival (PFS) reached 107 and 49 months, respectively, far exceeding those previously reported in the literature. Furthermore, the patient experienced an improvement in quality of life. These findings support multidisciplinary care as the cornerstone of long-term survival in pancreatic cancer. As an integral component of immunomodulation, DC-CIK cell therapy remodels the tumor microenvironment to facilitate other treatments, making it a defining therapeutic decision for patients with advanced pancreatic cancer.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1908017","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:36:35Z","timestamp":1789709795000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Multidisciplinary treatment incorporating autologous DC-CIK cell therapy induces long-term survival in advanced pancreatic cancer: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Shanshan","family":"Chen","sequence":"first","affiliation":[{"name":"Fujian Provincial Key Laboratory of Tumor Biotherapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunqing","family":"Xie","sequence":"additional","affiliation":[{"name":"Fujian Provincial Key Laboratory of Tumor Biotherapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohua","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Su","sequence":"additional","affiliation":[{"name":"Fujian Provincial Key Laboratory of Tumor Biotherapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangmei","family":"Xu","sequence":"additional","affiliation":[{"name":"Fujian Provincial Key Laboratory of Tumor Biotherapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijia","family":"Liu","sequence":"additional","affiliation":[{"name":"Fujian Provincial Key Laboratory of Tumor Biotherapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuhong","family":"Zheng","sequence":"additional","affiliation":[{"name":"Cell Therapy Research Center, Xiamen Humanity Hospital","place":["Xiamen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinying","family":"Liu","sequence":"additional","affiliation":[{"name":"Fujian Provincial Key Laboratory of Tumor Biotherapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Sun","sequence":"additional","affiliation":[{"name":"Fujian Provincial Key Laboratory of Tumor Biotherapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital","place":["Fuzhou, China"]},{"name":"Department of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70035","article-title":"Advances in pancreatic cancer early diagnosis, prevention, and treatment: The past, the present, and the future","volume":"76","author":"Mannucci","year":"2026","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.50756","article-title":"NALIRIFOX, FOLFIRINOX, and gemcitabine with nab-paclitaxel as first-line chemotherapy for metastatic pancreatic cancer: A systematic review and meta-analysis","volume":"7","author":"Nichetti","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B3","doi-asserted-by":"publisher","first-page":"7055","DOI":"10.3390\/ijms26157055","article-title":"Advances in the management of pancreatic cancer: Current strategies and emerging therapies","volume":"26","author":"Peshin","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71637","article-title":"Efficacy and safety of combination therapy with immune checkpoint inhibitors and chemotherapy with gemcitabine and nab-paclitaxel in pancreatic cancer: A systematic review","volume":"15","author":"Sohrabi","year":"2026","journal-title":"Cancer Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1056\/NEJMc2208623","article-title":"Neoantigen T-cell receptor gene therapy in pancreatic cancer","volume":"387","author":"Simnica","year":"2022","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13273","article-title":"Hurdles race for CAR T-cell therapy in digestive tract cancer","volume":"320","author":"Kronig","year":"2023","journal-title":"Immunol Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v17.i2.114423","article-title":"Immunosuppressive tumor microenvironment shape pancreatic cancer unresponsive to current immunotherapies","volume":"17","author":"Li","year":"2026","journal-title":"World J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s43018-022-00500-z","article-title":"Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1\/CXCR2 results in antitumor immunity and durable response in pancreatic cancer","volume":"4","author":"Gulhati","year":"2023","journal-title":"Nat Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioactmat.2025.06.010","article-title":"Synergistic therapy for pancreatic cancer by deactivating cancer-associated fibroblasts and driving T-cell migration into tumor microenvironment using nanochaperone delivery system","volume":"52","author":"Chen","year":"2025","journal-title":"Bioact Mater"},{"key":"B10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13148-026-02081-5","article-title":"Epigenetic modulation to overcome immune suppression in pancreatic cancer","volume":"18","author":"Drndakova","year":"2026","journal-title":"Clin Epigenet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s00262-025-04274-y","article-title":"Non-genetically modified adoptive cell therapies for solid tumors: Current landscape and future challenges","volume":"75","author":"Luo","year":"2026","journal-title":"Cancer Immunol Immunother"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1186\/s12967-024-05940-y","article-title":"Combined immunotherapy with dendritic cells and cytokine-induced killer cells for solid tumors: a systematic review and meta-analysis of randomized controlled trials","volume":"22","author":"Jiang","year":"2024","journal-title":"J Transl Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000024519","article-title":"Cytokine-induced killer cells\/dendritic cells and cytokine-induced killer cells immunotherapy for the treatment of esophageal cancer: A meta-analysis","volume":"100","author":"Yuan","year":"2021","journal-title":"Med (Baltimore)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2147\/ott.s143382","article-title":"Clinical applications of dendritic cells-cytokine-induced killer cells mediated immunotherapy for pancreatic cancer: an up-to-date meta-analysis","volume":"10","author":"Zhang","year":"2017","journal-title":"Onco Targets Ther"},{"key":"B15","article-title":"Efficacy of DC-CIK-based immunotherapy combined with chemotherapy in the treatment of intermediate to advanced non-small cell lung cancer","volume":"13","author":"Wang","year":"2021","journal-title":"Am J Transl Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2013.1672","article-title":"Requirement for a standardised definition of advanced gastric cancer","volume":"7","author":"A Des","year":"2014","journal-title":"Oncol Lett"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-026-00699-6","article-title":"Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer","volume":"395","author":"O'Reilly","year":"2026","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/s0889-8588(15)00091-x","article-title":"Daraxonrasib in previously treated advanced RAS-mutated pancreatic cancer","volume":"394","author":"Wolpin","year":"2026","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/s41598-024-84284-5","article-title":"Preclinical evaluation of DC-CIK cells as potentially effective immunotherapy model for the treatment of glioblastoma","volume":"15","author":"L\u00fcck","year":"2025","journal-title":"Sci Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2018.1564561","article-title":"Cytokine-induced killer cells co-cultured with non-cell derived targeting peptide-loaded dendritic cells induce a specific antitumor response","volume":"20","author":"Liu","year":"2019","journal-title":"Cancer Biol Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12964-026-02770-x","article-title":"Therapeutic potential of cytokine-induced killer cell therapy for renal cell carcinoma and prostate cancer","volume":"24","author":"Lee","year":"2026","journal-title":"Cell Commun Signal"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1633100","article-title":"Mechanisms and clinical advancements of cell-based immunotherapies in non-small cell lung cancer: an integrated perspective","volume":"16","author":"Yang","year":"2025","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2013.1200","article-title":"Cytokine-induced killer cell therapy for advanced pancreatic adenocarcinoma: A case report and review of the literature","volume":"5","author":"Li","year":"2013","journal-title":"Oncol Lett"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1566-3","article-title":"Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer","volume":"63","author":"Chung","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.3390\/cancers17081319","article-title":"Recent advances and challenges in the treatment of advanced pancreatic cancer: An update on completed and ongoing clinical trials","volume":"17","author":"Shenoy","year":"2025","journal-title":"Cancers (Basel)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1908017\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T08:57:30Z","timestamp":1792054650000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1908017\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":25,"alternative-id":["10.3389\/fimmu.2026.1908017"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1908017","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"1908017"}}